Tujuan tulisan ini adalah untuk membandingkan penurunan tekanan intraokuler (TIO) 25,88 ± 2,55 mmHg (p=0,354). Pada hari ke 7 pengobatan, TIO untuk masing-masing grup sebesar 16,75 + 1,92 dan 21,25 + 3,09 (p=0,001 25.88 ± 2.55 mmHg (p=0.354). At day 7, the IOP were consecutively 16.75 + 1.92 mmHg and 21.25 + 3.09 mmHg (p=0.001) and at day 14 IOP were 13.94 + 2.02 mmHg and 19.25 + 2.18 mmHg (p=000 
At present time, timolol an adrenergic beta-blocker, is the first line drug for chronic primary angle closure glaucoma (CPACG) treatment. 1 Timolol works by reducing the production of aqueous humor without affecting its outflow. The IOP lowering effect of timolol 0.5% twice a day occurs after two hours of administration and lasts for 24 hours. The IOP lowering effect is about 4-6 mmHg. 1 The Advanced Glaucoma Intervention Study (AGIS) has reported that timolol 0.5% cannot be used as a single therapy on 50% of glaucoma cases, and additional antiglaucoma agent is needed. 2 Presently, there is a prostaglandin analog group of drugs for the lowering of IOP in glaucoma. The mechanism of action of this drug in lowering IOP is by improving aqueous humour outflow through the uveoscleral path. 3 A previous report from a multicenter study on the use of prostaglandin analog (latanaprost) on CPACG for 12 weeks showed that latanaprost reduced IOP greater than timolol. 4 The effect of latanoprost in lowering IOP is not influenced with wider peripheral anterior synechia. 5 Another prostaglandin analog is Travoprost which also showed effectiveness in lowering IOP on primary open angle glaucoma and ocular hypertension. [6] [7] [8] During sixmonth trial in a clinical testing phase III, Travoprost was found to be more effective in reducing IOP compared to timolol. The IOP reduction was about 30% -33% or an average of less than 17 mmHg, and there was no tendency for IOP to rise. 6 Pivotal studies showed that Travoprost was an effective single therapy and optimal effect was achieved when Travoprost was given at night. [4] [5] [6] [7] In an other study comparing Travoprost, latanoprost and bimatoprost for 12 weeks on subjects with primary open angle glaucoma and ocular hypertension, all three drug were found to have the same potency in reducing IOP, but no study of the effect of Travoprost on primary angle closure glaucoma has been done. 8 Compared to other prostaglandin analogs which are partial agonist, Travoprost is a full agonist, which meant the drug has a high affinity to prostaglandin receptor and will produce maximal effect. 8 A further advantage is that Travoprost is more stable compared to latanaprost in room temperature. 5 At the present time, there is insufficient data regarding the use of Travoprost on CPACG.
The objective of this study was to compare IOP reduction after instillation of travoprost 0.004% eye drops with that of timolol 0.5 % on CPACG.
METHODS
This study was a cross-over intervention, randomized double blind trial. Subjects were derived consecutively from all subjects with previously treated CPACG at the Glaucoma Division, Department of Ophthalmology Faculty of Medicine of the University of Indonesia / National Central General Hospital Jakarta from April 2005 to July 2005.
The inclusion criteria for subjects were: CPACG subject, aged 40 years or more; initial CD ratio between 0.5 -0.7; who had undergone peripheral iridectomy with IOP between 21 mmHg -30 mmHg without medical therapy; CPACG subject who had undergone trabeculetomy IOP between 21 mmHg -30 mmHg with no therapy; and subject who had undergone peripheral iridectomy with or without trabeculectomy IOP 21 mmHg or less, and receiving medical therapy. All subjects were washed out and evaluated every week for three weeks with IOP between 21 mmHg -30 mmHg, and willing to sign a consent form.
The exclusion criteria were: CPACG subject with no compliance to a treatment regimen; subject with no compliance to scheduled follow up; subject contraindicated for Travoprost and timolol; and subject with serious systemic drug side effects (asthma, cardiac disorder).
Subjects of the study were randomly divided into A and B group. The subject in group A received Travoprost 0.004% eye drop once a day, while subjects in group B received timolol 0.5% twice a day. Every subject of the study from both group were given two bottles of eye drops identical in form and size. The first bottle was labeled "morning" and the second bottle was labeled "night". Subjects in group A were given a bottle labeled "morning" containing placebo and the bottle labeled "night" containing Travoprost 0.004%. Subjects in group B were given 2 bottles labeled "morning" and "night", both containing timolol 0.5%.
Anamnesis was taken regarding age, gender, occupation, and history of systemic as well as topical drug use. Visual acuity was examined using the Snellen chart, anterior segment was examined by slit lamp, anterior chamber angle by slit lamp and goniolens (to grade angle closure according to Shaffer) and IOP was measured with Goldmann aplanation tonometry. Evaluations of compliance and applanation tonometry for IOP were performed on day 1, 7, and 14.
The data were analyzed by Wilcoxon, paired T, unpaired T tests for the appropriate data set using SPSS version 10.
RESULTS
Sixteen subjects (32 eyes) met the inclusion criteria and were included in this study. Out of the 16 subjects meeting the inclusion criteria of the study, 9 (56.75%) subjects were post laser peripheral iridectomy, 4 (25%) were post trabeculectomy, and 3 (18.25%) subjects were post peripheral iridectomy and trabeculectomy. The subjects were comparable on entry for this study (Table 1) . Our study did not find serious systemic side effect in both groups. Table 2 shows that mean IOP on day 1, day 7 and day 14 after therapy in both groups were decreased. However, reduction of IOP was greater in the Travoprost group. Mean IOP on day 1, day 7 and day 14 reached 21 mmHg in the Travoprost group while in the timolol group this value was achieved only by day 14. Average IOP between the two groups on each follow up showed that reduction in IOP were faster and greater in the Travoprost than the timolol group. 
DISCUSSION
Some limitations in this study were: (1) the study was conducted in one hospital (Central General Hospital in Jakarta) only; (2) the number of subject was small; (3) the duration of the observation was short; and (4) IOP was measurement only taken once on each follow-up, without measuring diurnal variation. It was realized that a single measurement of IOP may be not enough for optimal management of glaucoma, and IOP measurement need to be performed several times within 24 hours, especially to observe diurnal IOP variation as stated by a previous study. 9 For diurnal fluctuation, IOP measurements need to be conducted at least four times a day with the subjects hospitalized. In this study IOP measurement was conducted only once, that is on every follow up, and therefore IOP diurnal fluctuation cannot be evaluated. This was due to the fact that most of the subjects in this study were women who refused to be hospitalized because of family responsibilities, such as taking care of their children and husbands. Other reasons were the great distance between their homes and the hospital making it impossible to come to the hospital several times a day for follow ups. This was why the time for IOP measurement was between 8 -10 o'clock in the morning of each follow up, when the IOP rise is expected to be the highest.
In this study, the average IOP between the two groups on each follow up showed that the decrease in IOP were faster and greater in the Travoprost group than in the timolol group. No other study was found regarding this finding on CPACG. However, previous studies have revealed that Travoprost was more effective than timolol in primary open angle glaucoma. 6 There were no serious systemic side effects in both groups. However, a previous study noted that the reduction in IOP after administration of timolol was not up to expectation and some serious systemic side effects were found; timolol was also unable to suppress diurnal fluctuation. 11.12 In another study lasting for three months, there was a reduction of 6.1 ± 0.2 mmHg from the initial IOP in CPACG. 13 While in another study where timolol was administered for 2 weeks, there was a reduction of 5.7 ± 0.7 mmHg or 23% in IOP in CPACG. 11 In this study, IOP reduction in the timolol group on day 14 was 6.63 ± 2.25 mmHg compared to baseline IOP or 25.35%. This finding supports a previous study which found that timolol 0.5% reduced IOP by 25% to 30%. 6 The ocular hypotensive effect can decrease (long term drift) with long term (a few months/years) administration of timolol. 9,10 IOP will reach a stable phase of 25% reduction of pre-treatment IOP.
The findings in this were based only on a single IOP measurement taken between 8.00 to 10.00 AM, while a previous study lasting 12 months on open angle glaucoma and ocular hypertension comparing Travoprost, Latanoprost and timolol, where IOP was measured on the second week and then every month, measurements were conducted at 8 o'clock in the morning, 10 o'clock in the morning and 4 o'clock in the afternoon. IOP reduction for the Travoprost group was significant for each measurement when compared to pretreatment initial IOP. Average IOP reduction showed that Travoprost reduced IOP all day long and produced significantly greater IOP reduction at 4 o'clock in the afternoon. 14 In conclusion, both Travoprost 0.004% and timolol 0.5% eye drops can reduce IOP in chronic primary angle closure glaucoma, but Travoprost reduced IOP faster and greater when compared to timolol.
